{
    "clinical_study": {
        "@rank": "99033", 
        "acronym": "ITP", 
        "arm_group": [
            {
                "arm_group_label": "Antioxidant, drug therapy for ITP", 
                "arm_group_type": "Experimental", 
                "description": "interventional arm 1 and will receive antioxidant therapy (Antox tablets  ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for  ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months."
            }, 
            {
                "arm_group_label": "drug therapy for ITP", 
                "arm_group_type": "Active Comparator", 
                "description": "drug therapy for ITP according to ASH, 2011 guidelines."
            }
        ], 
        "brief_summary": {
            "textblock": "Oxidative stress occurs as a result of increased activity of free radical-producing enzymes,\n      decreased activity of free radical-removing enzymes, and insufficient levels of\n      antioxidants. The most sensitive molecules to oxidation are lipids. Loss of cell membrane\n      elasticity, increased cell fragility, and a shortened cellular life span results from\n      oxidation of cell membrane lipids."
        }, 
        "brief_title": "Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "Free oxygen radicals may have an effect on the structural and functional damage of platelets\n      and plays a role in pathogenesis of thrombocytopenia in both, acute and chronic ITP.\n\n      Selenium is an essential mineral found in small amounts in the body. It works as an\n      antioxidant, especially when combined with other antioxidants as  vitamin E , A and C.\n      Antioxidants neutralize free radicals and may reduce or even help prevent some of the damage\n      they cause.\n\n      aim of this study is to assess oxidant and antioxidant systems initially in patients with\n      acute and chronic immune thrombocytopenia (ITP) and 6 months later.Another aim of the study\n      is to evaluate effect of antioxidant therapy on bleeding score, platelet count and\n      antioxidant status during 6 months follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. All patients less than 18 years with primary ITP; at initial presentation with\n             platelet count less than 40 x 109/L attended Ain Shams Hematology clinic Children\n             hospital from January 2013 and followed-up for 6 months.\n\n             2. For acute ITP, patients will be newly diagnosed (about one month within the\n             diagnosis).\n\n             3. For chronic (12-24 months) and persistent (3-12 months) ITP patients.\n\n        Exclusion Criteria:\n\n          1. Patients' platelet count more than 40 x 109/L.; or above 18 years\n\n          2. Patients with secondary cause for thrombocytopenia.\n\n          3. Patients with any there associated chronic illness affecting oxidant status"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763658", 
            "org_study_id": "Antioxident in ITP"
        }, 
        "intervention": [
            {
                "arm_group_label": "Antioxidant, drug therapy for ITP", 
                "description": "effect of antioxidant on disease outcome", 
                "intervention_name": "Antox tablets(Mepaco)", 
                "intervention_type": "Drug", 
                "other_name": "antioxidant drug"
            }, 
            {
                "arm_group_label": [
                    "Antioxidant, drug therapy for ITP", 
                    "drug therapy for ITP"
                ], 
                "description": "drugs will be selected according to ASH,2011 guidelines", 
                "intervention_name": "drug therapy for ITP", 
                "intervention_type": "Other", 
                "other_name": [
                    "dexamethasone", 
                    "prednisolone", 
                    "solumedrol", 
                    "Anti-D", 
                    "intravenous immunoglobulin", 
                    "romioplastin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antioxidants", 
                "Dexamethasone", 
                "Prednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Immunoglobulins", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ITP, antioxidant therapy, oxidant status", 
        "lastchanged_date": "January 8, 2013", 
        "location": {
            "contact": {
                "last_name": "Mohsen Saleh Elalfy, professor"
            }, 
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "hematology clinic ,pediatrics hospital, Ain Shams University hospital Cairo, Egypt"
            }, 
            "investigator": {
                "last_name": "Mohsen Saleh Elalfy, professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy", 
        "overall_contact": {
            "email": "dr_yasmi@yahoo.com", 
            "last_name": "yasmine I Elhenawy, lecturer", 
            "phone": "0104084038"
        }, 
        "overall_official": {
            "affiliation": "Ain Shams University", 
            "last_name": "Mohsen S Elalfy, professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "oxidant and antioxidant systems initially in patients with acute and chronic immune thrombocytopenia (ITP)", 
            "measure": "oxidant status in ITP", 
            "safety_issue": "Yes", 
            "time_frame": "6 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763658"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ain Shams University", 
            "investigator_full_name": "Mohsen Saleh Elalfy", 
            "investigator_title": "professor of pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "antioxidant therapy on bleeding score, platelet count and antioxidant status", 
            "measure": "antioxidant therapy", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Ain Shams University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ain Shams University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}